Class of Stock [Axis] Common Stock, par value $0.001 Warrants to Purchase Common Stock Related and Nonrelated Parties [Axis] Nonrelated Party [Member] Related Party [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Noncontrolling Interest [Member] Retained Earnings [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] License Agreement [Member] April Purchase Agreement [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 3 [Member] Consolidated Entities [Axis] NexGel [Member] CGNJV [Member] Subsegments Consolidation Items [Axis] Reportable Subsegments [Member] Business Combination [Axis] CG Converting and Packaging LLC [Member] C.G. Laboratories Inc. [Member] Variable Interest Entity, Primary Beneficiary [Member] Geographical [Axis] PANAMA Celularity License Agreement [Member] Asset Class [Axis] Property, Plant and Equipment [Member] Long-Lived Asset, Class [Axis] Machinery and Equipment [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Furniture and Fixtures [Member] Leasehold Improvements [Member] Construction in Progress [Member] Intangible Asset, Finite-Lived, Class [Axis] License Agreement Intangible Assets [Member] Technology-Based Intangible Assets [Member] Customer-Related Intangible Assets [Member] Trade Names [Member] Marketing-Related Intangible Assets [Member] Silly George Acquisition [Member] Technology Related and Customer Related Intangibles [Member] Debt Instrument [Axis] JV Notes Payable [Member] Economic Injury Disaster Loan [Member] Series A Convertible Notes [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Convertible Promissory Notes [Member] Placement Agent Warrant [Member] Long-Term Debt, Type [Axis] Convertible Debt [Member] Series A Convertible Note [Member] Plan Name [Axis] 2019 Plan [Member] Financial Instrument [Axis] Incentive Stock Options [Member] Title and Position [Axis] Executive Officer [Member] Chief Financial Officer [Member] Award Type [Axis] Share-Based Payment Arrangement, Option [Member] Equity Option [Member] Restricted Stock Units (RSUs) [Member] Separation Agreement [Member] Common Stock Warrants [Member] Awards Granted Outside 2019 Plan [Member] Legal Entity [Axis] STADA Arzneimittel AG [Member] Customer [Axis] Customer One [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Accounts Receivable [Member] Customer Two [Member] Customer Three [Member] CEO of C.G. Laboratories Inc. [Member] Unsecured Convertible Promissory Note [Member] Warrant [Member] Brian J. Kieser [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Defined Benefit Plan [Table] Defined Benefit Plan Disclosure [Line Items] ASSETS: Current Assets: Cash Restricted cash Accounts receivable, net Inventory, net Prepaid expenses and other current assets Total current assets Goodwill Intangibles, net Property and equipment, net Operating lease - right of use asset Investment in NexGelRx Other assets Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities: Accounts payable - related party Accrued expenses and other current liabilities Current portion of note payable Partnership accrued advance Current portion of finance lease liability Current portion of operating lease liability Derivative liability, at fair value Total current liabilities Operating lease liabilities, net of current portion Financing lease liability, net of current portion Convertible notes payable, net of debt discount Notes payable, net of current portion Total liabilities Commitments and Contingencies (Note 16) Stockholders’ Equity Preferred stock, par value $0.001 per share, 5,000,000 shares authorized, no shares issued and outstanding Common stock, par value $0.001 per share, 25,000,000 shares authorized; 9,700,022 and 8,475,693 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively Additional paid-in capital Accumulated deficit Total NexGel stockholders’ equity Non-controlling interest in joint venture Total stockholders’ equity Total liabilities and stockholders’ equity Statement of Financial Position [Abstract] Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues, net Cost of revenues Gross margin Operating expenses: Research and development Selling, general and administrative Total operating expenses Loss from operations Other income (expense): Interest income (expense), net Changes in fair value of derivative liability and warrant modification expense Loss on issuance of convertible debt Other expense Other income Total other income (expense), net Loss before income taxes Income tax expense Net loss Less: Income attributable to non-controlling interest in joint venture Net loss attributable to NexGel stockholders Net loss per common share - basic Net loss per common share - diluted Weighted average shares used in computing net loss per common share - basic Weighted average shares used in computing net loss per common share – diluted Balance Balance, shares Restricted stock issuances Restricted stock issuances, shares Issuance of securities for the conversion of convertible notes payable and accrued interest Issuance of securities for the conversion of convertible notes payable and accrued interest, shares Net income (loss) Stock-based compensation - stock options/restricted Warrants issued in conjunction with the conversion of convertible notes payable Share-based compensation and restricted stock issuances Share-based compensation and restricted stock issuances, shares Balance Balance, shares Statement of Cash Flows [Abstract] Operating Activities Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Share-based compensation and restricted stock vesting Amortization of right-of-use asset Amortization of debt discount Changes in fair value of warrant liability and warrant modification expense Loss on issuance of convertible note Changes in operating assets and liabilities: Accounts receivable, net Inventory Prepaid expenses and other assets Accounts payable Accounts payable – related party Accrued expenses and other current liabilities Partnership advance Operating lease liability Deferred revenue Net Cash Used in Operating Activities Investing Activities Capital expenditures Investment in BioNx (License Agreement) Net Cash Used in Investing Activities Financing Activities Proceeds from convertible notes payable, net Payment of contingent consideration Principal payment on financing lease liability Financing costs Principal payments of notes payable Net Cash Provided by (Used in) Financing Activities Net Increase (Decrease) in Cash * Cash and restricted cash – Beginning of period Cash and restricted cash  – End of period Supplemental Disclosure of Cash Flows Information Interest Taxes Supplemental Non-cash Investing and Financing activities Issuance of convertible notes and other liabilities in conjunction with license agreement Issuance of securities for the conversion of convertible notes payable and accrued interest Issuance of warrants in conjunction with convertible notes payable Debt issued at a discount Derivative liabilities recognized as debt discounts Initial recognition of ROU asset and operating lease liabilities Increase in cash Increase in restricted cash Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Equity Awards Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Insider Trading Arrangements [Line Items] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration Aggregate Available Rule 10b5-1 Arrangement Modified Non-Rule 10b5-1 Arrangement Modified Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Accounting Policies [Abstract] Description of Business and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements [Abstract] Going Concern Significant Accounting Policies and Estimates Segment Reporting [Abstract] Business Segments Variable Interest Entities Operating Leases Operating Leases Financing Lease Financing Lease Inventory Disclosure [Abstract] Inventory, net Property, Plant, and Equipment [Abstract] Property and Equipment, Net Intangible Asset, Goodwill and Other [Abstract] Intangible Assets Payables and Accruals [Abstract] Accrued Expenses and Other Current Liabilities Debt Disclosure [Abstract] Notes Payable Convertible Notes Payable Convertible Notes Payable Equity [Abstract] Common Stock Share-Based Payment Arrangement [Abstract] Share-based Compensation Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Risks and Uncertainties [Abstract] Concentrations of Risk Related Party Transactions [Abstract] Related Party Transactions Subsequent Events [Abstract] Subsequent Events Use of Estimates Segment Reporting Reclassifications Cash, Cash Equivalents and Restricted Cash Accounts Receivable, Net Inventory and Cost of Revenues Research and Development Property and Equipment, Net Impairment of Long-Lived Assets Goodwill and Intangible Assets Prepaid Expenses and Other Current Assets Other Assets Fair Value Measurements Equity Classified Warrants Offering Costs Revenue Recognition Share-based Compensation Income Taxes Leases Variable Interest Entity Accounting Pronouncements Issued But Not Yet Adopted Schedule of Cash and Cash Equivalents Schedule of Fair Value of Derivative Liabilities Schedule of Level 3 Roll-forward for Derivative Liabilities Schedule of Disaggregated Revenue by Sales Type Schedule of Reportable Segments Schedule of Consolidated Variable Interest Entities Schedule of Future Minimum Operating Lease Payments Schedule of Supplemental Cash Flows Information Related to Operating Leases Schedule of Future Minimum Financing Lease Payments Schedule of Supplemental Cash Flows Information Related to Financing Lease Schedule of Inventory Schedule of Property and Equipment Schedule of Breakdown of Identifiable Intangible Assets Schedule of Estimated Annual Amortization Expense Schedule of Accrued Expenses and Other Current Liabilities Schedule of Debt Instruments Schedule of Outstanding Convertible Debt Schedule of Reserved Common Stock For Issued Securities in Relation Schedule of Information about Incentive Plan Schedule of Incentive Stock Option Activity Schedule of Assumptions used in Share-based Compensation Schedule of Restricted Stock Units Granted Schedule of Common Stock Warrants Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Pay or deliver to aggregate upfront consideration Cash payment Payment of debt Original principal amount Bears interest rate Debt conversion price Issued warrants to purchase of common stock, shares Contingent milestone payments Gross proceeds Warrant exercise price [custom:UnrestrictedCashBalance-0] Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Transaction cost Restricted cash Total cash and restricted cash shown in the statement of cash flows Derivative liability as of June 30, 2026 ($ in thousands) Balance at January 1, 2026 Initial recognition of derivative liability Changes in fair value Balance at June 30, 2026 Contract manufacturing Custom and white label finished goods manufacturing Consumer branded products Medical devices/other Biomaterial products Total Total Number of reportable segments Restricted cash Allowance for credit losses Reserve recorded against inventories Prepaid insurance General prepaid expenses and other current assets Investment fair value Segment Reporting [Table] Segment Reporting [Line Items] Advertising, marketing and amazon fees General and administrative Total Selling, general and administrative Operating expenses Income (loss) from operations Total Assets Consolidation, Less-than-Wholly-Owned Subsidiary, Parent Ownership Interest, Effect of Change [Table] Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] ASSETS Inventory Accounts payable Finance lease liability, short term Operating lease liability, current portion Operating lease liability, net of current portion Finance lease liability, long term Restructuring Cost [Table] Restructuring Cost and Reserve [Line Items] Acquisition percentage Payment to acquire business Lessee, Lease, Description [Table] Option to extend Area of office space Operating lease expense Weighted average discount rate Weighted average remaining lease term Schedule Of Future Minimum Operating Lease Payments 2026 2027 2028 2029 2030 Thereafter Total undiscounted operating lease payments Less: Imputed interest Present value of operating lease liability Schedule Of Supplemental Cash Flows Information Related To Operating Leases Operating cash flows from operating leases Schedule Of Future Minimum Financing Lease Payments 2026 2027 2028 2029 Thereafter Total undiscounted financing lease payments Less: Imputed interest Present value of financing lease liability Schedule Of Supplemental Cash Flows Information Related To Financing Lease Financing cash flows from financing lease Impairment Effects on Earnings Per Share [Table] Impairment Effects on Earnings Per Share [Line Items] Financing lease liability included in property and equipment Weighted average interest rate Weighted average remaining lease term Raw materials Work-in-progress Finished goods Inventory, gross Less: Inventory reserve for excess and slow moving inventory Total Property, Plant, and Equipment [Table] Property, Plant, and Equipment [Line Items] Property and equipment, gross  Useful life (years) Less: accumulated depreciation and amortization Property and equipment, net Depreciation expense Intangible Asset, Finite-Lived [Table] Intangible Asset, Finite-Lived [Line Items] Intangible asset, gross Accumulated amortization Total identifiable intangible assets, net 2026 (remainder of year) 2027 2028 2029 2030 Subtotal Indefinite lived intangible assets (subject to impairment analysis) Total Finite-lived intangible asset Cash Convertible promissory note Intangible assets estimated useful life Intangible assets Expected life Amortization expense Salaries, benefits, and incentive compensation Other Total accrued expenses and other current liabilities Short-Term Debt [Table] Short-Term Debt [Line Items] 2026 2027 2028 2029 2030 Thereafter Total Less: current portion of notes payable Long-term portion of notes payable Agreements terms Interest rate Debt instrument periodic payment Principal balance amount Notes payable Borrowing capacity Loan advance Principal and accrued interest Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Total gross principal Unamoritzed debt discount – Convertible Promissory Notes Accrued interest Convertible debt, long-term, net of debt discount Aggregate principal amount Cash proceeds Bears interest rate Debt discount Debt contractual amount Interest expense Debt effective interest rate Debt converted principal amount Debt converted principal amount, shares Principal amount Unamortized discount Debt instrument carrying amount Interest rate Warrant issued Warrant issuance term Percentage of principal amount Fair value of embedded derivative liabilities Cost of finanacing Accrued interest Net carrying amount Class of Warrant or Right, Outstanding Debt Instrument, Repurchase Amount Share-based compensation plan Warrants to purchase common stock Restricted stock units Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Awards Reserved For Issuance Awards Issued Awards Exercised Awards Available for Grant Number of Options, Outstanding, Balance Weighted Average Exercise Price, Outstanding Balance Weighted Average Remaining Contractual Term Number of Options, Outstanding, Granted Weighted Average Exercise Price, Granted Weighted Average Remaining Contractual Term, Granted Number of Options, Outstanding, Exercised Weighted Average Exercise Price, Exercised Number of Options, Outstanding, Forfeited Weighted Average Exercise Price, Forfeited Number of Options, Outstanding, Balance Weighted Average Exercise Price, Outstanding Balance Number of Options, Exercisable Weighted Average Exercise Price, Exercisable Weighted Average Remaining Contractual Term, Exercisable Volatility Risk-free interest rate Dividend yield Expected term Number of units outstanding beginning Weighted average grant date fair value outstanding beginning Number of units, granted Weighted average grant date fair value, granted Number of units, exercised and converted to common shares Weighted average grant date fair value, exercised and converted to common shares Number of units, forfeited Weighted average grant date fair value, forfeited Number of units outstanding ending Weighted average grant date fair value outstanding ending Number of units exercisable Weighted average grant date fair value exercisable Number of warrants, outstanding beginning balance Weighted average exercise price, outstanding beginning balance Weighted average remaining contractual term Number of warrants, granted Weighted average exercise price, granted Weighted average remaining contractual term, granted Number of warrants, expired Weighted average exercise price, expired Number of warrants, outstanding ending balance Weighted average exercise price, outstanding ending balance Number of warrants, exercisable Weighted average exercise price, exercisable Weighted average remaining contractual term, exercisable Number of authorized shares of common stock Additional common stock reserved for issuance Number of options, granted Shares been awarded or exercised, shares Additional shares authorized Shares available for grant Exercise price of options Number of stock option vested Number of stock option vested remaining Vested outstanding stock options intrinsic value Unrecognized share based compensation Period of recognition of stock based compensation expense Granted, shares Shares authorized for issuance Grant price per share Unrecognized share based compensation expense Stock based compensation Intrinsic value of vested outstanding warrants Loss Contingencies [Table] Loss Contingencies [Line Items] Partnership accrued advance Advance in partnership restricted cash Partnership accrued advance Proceeds from other deposits Restricted cash remaining Contingent milestone payments Loss contingency, damages sought, value Concentration Risk [Table] Concentration Risk [Line Items] Concentration risk, percentage Cash, exceeding limit Related Party Transaction [Table] Related Party Transaction [Line Items] Other payable - related party Debt instrument convertible shares Purchase of shares of common stock up to Aggregate principal amount outstanding Warrants to Purchase Common Stock. Common Stock, par value $0.001. Partnership accrued advance. Changes in fair value of warrant liability. Adjustment in additional paid in capital warrants issued in conjunction with conversion of convertiable notes payable. Initial recognition of ROU asset and operating lease liabilities Issuance of warrants in conjunction with convertible notes payable Issuance of securities for conversion of convertible notes payable and accrued interest. Increase in restricted cash. License Agreement [Member] April Purchase Agreement [Member] Unrestricted cash balance. Contingent milestone payments. Prepaid Expenses And Other Current Assets [Policy TextBlock] Other Assets [Policy TextBlock] Warrant liabilities. Offering Costs [Policy Text Block] Revenue from contract manufacturing. Revenue from finished goods. Revenue from consumer products. Medical devices/other. Revenue classified as biomaterial products. Variable Interest Entity [Policy Text Block] NexGel [Member] CGNJV [Member] CG Converting and Packaging LLC [Member] C.G. Laboratories Inc. [Member] Celularity License Agreement [Member] Lessee operating lease liability payments due after year four. The tabular disclosure of supplemental cash flows information related to leases. Finance lease liability payments due year there after four. Financing cash flows from financing lease. License Agreement Intangible Assets [Member] Silly George Acquisition [Member] Technology Related and Customer Related Intangibles [Member] JV Notes Payable [Member] Economic Injury Disaster Loan [Member] Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fourth fiscal year following current fiscal year. Series A Convertible Notes [Member] 2019 Plan [Member] Incentive Stock Options [Member] Awards Granted Outside 2019 Plan [Member] Share based compensation arrangement by share based payment award number of shares available for exercised. Share based compensation arrangement by share based payment award options cancelled in period. Share based compensation arrangement by share based payment award options cancelled in period. Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term 2. Share based compensation arrangement by share based payment award equity instruments other than options exercisable non vested number. Share based compensation arrangement by share based payment award equity instruments other than options exercises in period weighted average grant date fair value. Share based compensation arrangement by share based payment award equity instruments other than options non vested exercisable weighted average grant date fair value. Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event. The number of shares into which fully or partially vested warrants outstanding as of the balance sheet date can be currently converted under the option plan. Weighted average price at which grantees can acquire the shares reserved for issuance under the warrants plan. Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants. Weighted average price at which option holders acquired shares when converting their warrants into shares. Weighted average price at which grantees could have acquired the underlying shares with respect to warrants that were terminated. Weighted average price at which grantees could have acquired the underlying shares with respect to warrants that were terminated. Weighted average price at which grantees could have acquired the underlying shares with respect to warrants of the plan that expired. The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of warrants outstanding and currently exercisable under the warrants plan. Weighted average remaining contractual term for non option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Weighted average remaining contractual term, exercisable. Share based compensation arrangement by share based payment award non options outstanding weighted average remaining contractual term granted. Customer One [Member] Customer Two [Member] Customer Three [Member] CEO of C.G. Laboratories Inc. [Member] Unsecured Convertible Promissory Note [Member] Share based compensation arrangement by share based payment award options vested number of shares remaining. Rule 10b5-1 Arrangement Modified Non-Rule 10b5-1 Arrangement Modified Loss on issuance of convertible debt. Issuance of convertible notes in exchange for accounts payable. Derivative liabilities recognized as debt discounts. Increase in cash., Convertible Notes Payable Disclosure [Text Block] Separation Agreement [Member] Common Stock Warrants [Member] STADA Arzneimittel AG [Member] Brian J. Kieser [Member] Changes in fair value of derivative liability and warrant modification expense. Convertible notes derivative liabilities policy text block. Valuation Methodology [Policy Text Block] Fair Value Hierarchy [Policy Text Block] Convertible Promissory Notes [Member] Placement Agent Warrant [Member] Series A Convertible Note [Member] Debt issued at discount. Issuance of convertible notes and other liabilities in conjunction with license agreement. Assets, Current Liabilities, Current Liabilities Equity, Attributable to Parent Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Gross Profit Other Nonoperating Expense Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Net Income (Loss) Attributable to Noncontrolling Interest Shares, Outstanding Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Increase (Decrease) in Other Operating Assets Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Payments to Acquire Other Productive Assets Payments to Acquire Intangible Assets Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Payment for Contingent Consideration Liability, Financing Activities Finance Lease, Principal Payments Repayments of Notes Payable Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation IssuanceOfSecuritiesForConversionOfConvertibleNotesPayableAndAccruedInterest Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name Lessee, Operating Leases [Text Block] Lessee, Finance Leases [Text Block] Inventory Disclosure [Text Block] Convertible Notes Payable Disclosure [Text Block] Property, Plant, and Equipment [Policy Text Block] Share-Based Payment Arrangement [Policy Text Block] Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Derivative Liability Restricted Cash and Cash Equivalent, Current Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Finance Lease, Liability, to be Paid, Year One Finance Lease, Liability, to be Paid, Year Two Finance Lease, Liability, to be Paid, Year Three Finance Lease, Liability, to be Paid, Year Four FinanceLeaseLiabilityPaymentsDueYearThereafterFour Finance Lease, Liability, to be Paid Finance Lease, Liability, Undiscounted Excess Amount Finance Lease, Liability Finance Lease, Weighted Average Remaining Lease Term Inventory, Gross Inventory Adjustments Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization Intangible Asset, Finite-Lived, Accumulated Amortization Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year One Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Two Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Three Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Four Intangible Asset, Finite-Lived, after Accumulated Amortization Cash Equivalents, at Carrying Value Long-Term Debt, Maturity, Remainder of Fiscal Year Long-Term Debt, Maturity, Year One Long-Term Debt, Maturity, Year Two Long-Term Debt, Maturity, Year Three Long-Term Debt, Maturity, Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour Long-Term Debt Debt Instrument, Interest Rate During Period Interest Payable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableWeightedAverageGrantDateFairValue Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice Proceeds from Partnership Contribution Advances to Affiliate